Bio-Rad Laboratories Inc. (BIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, BIO scores 66 out of 100, earning a C+ and the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC 0.5%; FCF yield 3.64%), Whale 13F Flow at 17/20 (institutional accumulation and options positioning), Insider Conviction at 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 12/20 (Beta 1.04; sector sensitivity), and Forensic Balance Sheet at 16/20 (Altman Z 3.59; Piotroski F 7/9; Debt/Equity 0.16).

The profile is uneven. The weakest pillar is the cash engine, where a 0.5% ROIC and a 7/20 score signal that the business is not currently converting capital into high returns, even though the FCF yield of 3.64% provides some cash-generation support. The strongest pillars are institutional flow and the balance sheet, which together suggest that large holders are positioned constructively and that leverage is not a near-term constraint. For a prospective investor, the upside case rests on the balance-sheet strength and institutional interest persisting while operating returns improve; the valuation tradeoff is that the stock trades at a P/E of 13.5 (TTM) against an EV/EBITDA of 60.4, a combination that makes the earnings base look modest relative to the enterprise value. The "Watch for Breakout" label implies the rating is sensitive to whether returns on capital move meaningfully higher, which the source data does not forecast.

Bio-Rad Laboratories Inc. (BIO) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry, per the company profile. The source data identifies the company's market capitalization as $10.3B. Revenue is reported in the SEC financials at $2583.2M for FY 2025. The source data does not describe specific products, customer segments, or the mechanics of revenue generation beyond the sector and industry classification.

Per the SEC financials, operating income fell from $337.8M (FY 2023) to $269.0M (FY 2024) to $47.2M (FY 2025), while reported net income swung from losses to $759.9M in FY 2025. The market data reports a gross margin of 51.9%, an operating margin of 1.8%, and a net margin of 29.4%, with ROIC at 0.5%. The forensic balance sheet pillar cites an Altman Z-Score of 3.59 and a Piotroski F-Score of 7/9, with Debt/Equity at 0.16. Free cash flow was positive in each reported period, rising to $374.6M in FY 2025, and the source data shows debt roughly stable near $1.2B over FY 2024 and FY 2025.

Per the recent news feed, the headlines are broadly market-commentary in nature: a Yahoo Finance-syndicated quote page, a GuruFocus note describing the stock as down 3.0% while still overvalued, a Simply Wall St piece on investor reaction to a Vericheck kit expansion, and a Stock Titan notice that a 2 p.m. Pacific call is scheduled to discuss third-quarter results on Nov. 4. Each item is tagged with a yellow signal light and "MARKET WIRE" impact label. The Q3 results call is the one dated, company-specific catalyst in the feed. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no graph-derived catalysts are identified.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments, and the beta of 1.04 per the market data. An investor should not infer specific supplier or customer ripple effects from the source material.

• What are the specific drivers behind the gap between the 0.5% ROIC and the positive net margin of 29.4% and FY 2025 net income of $759.9M, and is the net income figure recurring?
• What do the Q3 results scheduled for Nov. 4 show regarding operating income trajectory from $47.2M in FY 2025?
• Why is the EPS field "N/A" for all three reported periods while TTM EPS is listed at 28.42?
• What is the cash balance for FY 2023, which the source data marks as unavailable?
• What does the institutional and options-positioning data within the whale pillar show at the holder level, given that holder data is not provided?